ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting

Friday, June 28, 2019

Submitted by

Claire Vernon

Source

Source Name: The Annals of Thoracic Surgery

Source URL: https://doi.org/10.1016/j.athoracsur.2019.01.086

Author(s)

Manne Holm, Fausto Biancari, Sorosh Khodabandeh, Riccardo Gherli, Juhani Airaksinen, Giovanni Mariscalco, Giuseppe Gatti, Daniel Reichart, Francesco Onorati, Marisa De Feo, Giuseppe Santarpino, Antonino S. Rubino, Daniele Maselli, Francesco Santini, Francesco Nicolini, Marco Zanobini, Eeva-Maija Kinnunen, Vito G. Ruggieri, Andrea Perrotti, Stefano Rosato, Magnus Dalén

Holm and colleagues evaluated perioperative bleeding after coronary artery bypass grafting (CABG) in patients who were taking P2Y₁₂ inhibitors. Patient outcomes from the European Multicenter Registry on Coronary Artery Bypass Grafting were included in the analysis, with 1,293 patients who received clopidogrel preoperatively and 1,018 who received ticagrelor. The authors observed a higher incidence of major bleeding in patients when these therapies were discontinued for fewer days prior to CABG, and they suggest postponing nonemergent procedures for at least 3 and 4 days after discontinuation of ticagrelor and clopidogrel, respectively.